

pRNFL as a marker of disability worsening in the medium/long term in patients with MS

Christian Cordano, MD, PhD, Bardia Nourbakhsh, MD, MAS, Michael Devereux, BS, Vincent Damotte, PhD, Daniel Bennett, BS, Stephen L. Hauser, MD, Bruce A. C. Cree, MD, PhD, MAS, Jeffrey M. Gelfand, MD, MAS, and Ari J. Green, MD, MCR

Correspondence
Dr. Green
agreen@ucsf.edu

Neurol Neuroimmunol Neuroinflamm 2019;6:e533. doi:10.1212/NXI.0000000000000533

MS is an inflammatory and neurodegenerative disease of the CNS (including the retina) that leads to progressive neurologic disability. Disability correlates with the degree of axonal pathology in the disease.^{1,2} The clinical course of MS is unpredictable, making the search for biomarkers associated with enhanced risk of disease progression a major unmet need. Spectral domain optical coherence tomography (SD-OCT) is a potential predictor of disability worsening up to 5 years of follow-up after a single evaluation of the peripapillary retinal nerve fiber layer (pRNFL).³ Time domain OCT (TD-OCT) is an older technology, characterized by lower axial resolution and slower acquisition speed (400 axial scans per second) resulting in lower resolution images and more frequent motion artifacts compared with SD-OCT.⁴ TD-OCT was used over 10 years ago to assess retinal neurodegeneration in patients with MS but only now has enough time passed to assess its actual predictive potential for clinical progression.

To investigate the capacity of TD-OCT measures to predict disability worsening in patients with MS, we performed a retrospective evaluation of 305 patients with MS (228 relapsing-remitting, 29 secondary progressive, 32 clinically isolated syndrome, 10 primary progressive MS according to 2005 McDonald criteria,⁵ and 6 with MS but unclear disease course) who had undergone Stratus TD-OCT (Carl Zeiss Meditec AG, Jena, Germany) from January 2006 to December 2008, collecting the values of the pRNFL and macular volume (MV). The Committee on Human Research at UCSF approved the study. All participants provided written informed consent. The baseline cohort characteristics are presented in the table. All patients had at least 1 measurement of the Expanded Disability Status Scale (EDSS) during the subsequent follow-up period. In our analyses, we used the most recent available EDSS. The median follow-up duration from the time of OCT to the most recent EDSS evaluation was 7.9 years (interquartile range 6.4–8.9 years, range 0.04–9.5 years); 91% of the cohort had >5 years of follow-up. The association between the baseline pRNFL and the subsequent EDSS was investigated using multivariable linear regression, adjusted for age and sex, taking into account the correlation of pRNFL thickness in the patient's 2 eyes (figure). For each 1- μ m decrease in the pRNFL, there was a 0.024 increase in EDSS (95% CI: 0.011–0.037; $p < 0.001$). In a sensitivity analysis, the results were similar (0.022 increase in the EDSS, 95% CI 0.035–0.01, $p = 0.001$) when analyzing only patients with >5 years of follow-up. A model adjusted for the presence of previous episodes of optic neuritis yielded similar results (a 1- μ m decrease in the RNFL was associated with a 0.024 increase in the EDSS; $p < 0.001$). There was no association with MV. The lack of consistent association of MV with disability worsening has previously been reported³ and may relate to the lack of segmentation from whole macular thickness where some layers increase volume and others lose volume during the course of disease. In addition, TD-OCT had poorer reproducibility for volume scans because of the low speed of image acquisition. These results show that TD-OCT and a single evaluation of pRNFL atrophy is

From the Department of Neurology (C.C., M.D., V.D., D.B., S.L.H., B.A.C.C., J.M.G., A.J.G.), UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA; and Department of Neurology (B.N.), Johns Hopkins University School of Medicine, Baltimore, MD.

Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NN.

The Article Processing Charge was funded by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Table Demographic and baseline characteristics and the follow-up data of the study population (number of patients = 305)


Female	65.7
Average age (SD), y	42.7 (11.8)
Average disease duration in years (SD)	10 (9.2)
Average most recent EDSS (SD)	2.9 (1.9)
Average days from OCT to EDSS (SD)	2,696.4 (655.0)
Median years from OCT to EDSS (IQR, range)	7.9 (6.4–8.9, 0.04 to 9.5)
Average RNFL thickness (SD)	88.9 (15.2)
Average ON-positive RNFL (SD) (N = 193) ^a	82 (16.4)
Average ON-negative RNFL (SD) (N = 410) ^a	91.9 (13.5)
% of patients using DMT at OCT visit	68.7
Average duration of DMT use at EDSS visit in years (SD)	10.3 (5.3)

Abbreviations: DMT = disease-modifying therapy; EDSS = Expanded Disability Status Scale; IQR = interquartile range; ON = optic neuritis; RNFL = retinal nerve fiber layer.

^a Seven eyes were excluded from the analysis because of poor quality (total number of eyes = 603).

useful in predicting disability up to 6–9 years later in MS—significantly longer than has been previously reported. A limitation of the study is the absence of the baseline EDSS in the entire cohort, which limited our ability to consider its influence as a confounder in the estimate of association between the baseline RNFL and subsequent EDSS. Recent meta-analyses show that the mean RNFL loss in a population of patients with optic neuritis is similar between TD-OCT and SD-OCT.^{6,7} However, despite the similarity in means at an

Figure Association of baseline RNFL with EDSS at the end of the follow-up period



RNFL = retinal nerve fiber layer.

individual level, SD-OCT is known to be more accurate. Stratus TD-OCT is no longer used in MS research because of the availability of more sophisticated OCT machines being able to quantify retinal measures with a much lower level of noise.⁸ Nevertheless, despite the effect on SDs, this noise does not affect the mean, and data from earlier iterations of the technology can be useful to indicate the association between retinal thinning and future disability.

Author contributions

C. Cordano: study concept and design, interpretation of data, and composition of the manuscript. B. Nourbakhsh: analysis and interpretation of data. M. Devereux and V. Damotte: acquisition of data and composition of the manuscript. D. Bennett: acquisition of data and supervision of the manuscript. S.L. Hauser and B.A.C. Cree: study supervision and composition of the manuscript. J.M. Gelfand: analysis and interpretation of data and composition of the manuscript. A.J. Green: study concept and design, analysis and interpretation of data, and composition of the manuscript.

Study funding

No targeted funding reported.

Disclosure

C. Cordano received research support from FISM and served as a consultant for Inception 5. B. Nourbakhsh received research support from Biogen, American Brain Foundation, National Multiple Sclerosis Society, and Patient-Centered Outcome Research Institute. M. Devereux reports no disclosures. V. Damotte received travel funding fromECTRIMS and ARSEP Foundation. D. Bennett reports no disclosures. S.L. Hauser served on the scientific advisory boards of Symbiotix, Annexon, Bionure, Molecular Stethoscope, Alector, and Neurona; received travel funding and speaker honoraria from F. Hoffmann La Roche; receives publishing royalties from McGraw-Hill Education; received writing support from F. Hoffmann La Roche; and received research support from the NIH, NMSS, and Conrad N. Hilton Foundation. B.A.C. Cree served on the scientific advisory board of Akili and consulted for AbbVie, Biogen, EMD Serono, GeNeuro, Novartis, and Sanofi Genzyme. J.M. Gelfand served on the DSMB for an NIA-funded study; is on the editorial board of *Neurology: Neuroimmunology & Neuroinflammation*; received publishing royalties from DynaMed Plus; consulted for Biogen; received research support from MedDay and research support (to UCSF) from Genentech; is PI of an institutional clinician training award from the NMSS; received compensation for medical-legal consulting; his spouse is an associate editor of *JAMA Neurology*; received honoraria from UpToDate; and consulted for Zosano, Eli Lilly, Biohaven, and eNeura. A.J. Green served on the scientific advisory boards of MedImmune, Novartis, Inception 5 Sciences, Pipeline, and Bionure; served as an associate editor of *JAMA Neurology* and editorial board member of *Neurology*; holds a patent for remyelination molecules and pathways; received research support from Novartis, Inception Sciences, NINDS, NIA,

NIH, NMSS, Sherak Foundation, and Hilton Foundation; holds stock or stock options in Inception 5, Pipeline, and Bionure; and served as an expert witness in Mylan Pharmaceuticals v Teva Pharmaceuticals. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NN.

Publication history

Received by *Neurology: Neuroimmunology & Neuroinflammation* July 19, 2018. Accepted in final form November 8, 2018.

References

1. Arnold DL, Matthews PM, Francis G, Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. *Magn Reson Med* 1990;14:154–159.
2. Frohman EM, Costello F, Stüve O, et al. Modeling axonal degeneration within the anterior visual system: implications for demonstrating neuroprotection in multiple sclerosis. *Arch Neurol* 2008;65:26–35.
3. Martinez-Lapiscina EH, Arnow S, Wilson JA, et al. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. *Lancet Neurol* 2016;15:574–584.
4. Leung CK, Chiu V, Weinreb RN, et al. Evaluation of retinal nerve fiber layer progression in glaucoma: a comparison between spectral-domain and time-domain optical coherence tomography. *Ophthalmology* 2011;118:1558–1562.
5. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. *Ann Neurol* 2005;58:840–846. Review.
6. Petzold A, de Boer JF, Schippling S, et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. *Lancet Neurol* 2010;9:921–932.
7. Petzold A, Balcer LJ, Calabresi PA, et al. Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. *Lancet Neurol* 2017;16:797–812.
8. Warner CV, Syc SB, Stankiewicz AM, et al. The impact of utilizing different optical coherence tomography devices for clinical purposes and in multiple sclerosis trials. *PLoS One* 2011;6:e22947.

Neurology[®] Neuroimmunology & Neuroinflammation

pRNFL as a marker of disability worsening in the medium/long term in patients with MS

Christian Cordano, Bardia Nourbakhsh, Michael Devereux, et al.
Neurol Neuroimmunol Neuroinflamm 2019;6;
DOI 10.1212/NXI.0000000000000533

This information is current as of December 21, 2018

Updated Information & Services	including high resolution figures, can be found at: http://nn.neurology.org/content/6/2/e533.full.html
References	This article cites 8 articles, 0 of which you can access for free at: http://nn.neurology.org/content/6/2/e533.full.html##ref-list-1
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): All Neuro-ophthalmology http://nn.neurology.org/cgi/collection/all_neuroophthalmology Multiple sclerosis http://nn.neurology.org/cgi/collection/multiple_sclerosis Optic nerve http://nn.neurology.org/cgi/collection/optic_nerve
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://nn.neurology.org/misc/about.xhtml#permissions
Reprints	Information about ordering reprints can be found online: http://nn.neurology.org/misc/addir.xhtml#reprintsus

Neurol Neuroimmunol Neuroinflamm is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Online ISSN: 2332-7812.

